| (Values in U.S. Thousands) | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 | Dec, 2019 |
| Sales | 64,700 | 130,490 | 31,240 | 0 | 0 |
| Sales Growth | -50.42% | +317.70% | unch | unch | unch |
| Net Income | -123,430 | -64,000 | -124,970 | -129,780 | -86,530 |
| Net Income Growth | -92.86% | +48.79% | +3.71% | -49.98% | -93.10% |
Poseida Therapeutics Inc (PSTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Poseida Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focuses on developing therapeutics for high unmet medical needs. The company is developing a pipeline of solutions for the treatment of hematological malignancies and solid tumors, as well as vivo programs for liver-directed gene therapies for rare diseases. In addition, it offers CAR-T therapies for the treatment for cancer. Poseida Therapeutics Inc. is based in San Diego, California.
Fiscal Year End Date: 12/31